Response Surface Methodology for Optimization of Ultrasound-Assisted Transdermal Delivery and Skin Retention of Asenapine Maleate
- 122 Downloads
Asenapine maleate (ASP) is an antipsychotic agent used in the treatment of schizophrenia and bipolar disorder. It has extremely low oral bioavailability of < 2%, necessitating the utilization of alternate route of administration. The objective of this work is to study and optimize the sonophoretic transdermal delivery and skin retention of ASP statistically, in Sprague-Dawley rat skin, using response surface methodology in Design of Experiments (DoE).
I-optimal design was employed, using the ultrasound (US) parameters viz., duration of US application, amplitude of US, and mode of US application (simultaneous application or pretreatment) as the input variables. Steady-state flux (Jss) of ASP and amount of drug retained in skin after 24 h was taken as the output responses.
The model and dependent variables were found to be significant and representative of the data and response surface. While passive diffusion yielded Jss of 2.575 μg/cm2/h, the same values with US application ranged from 8.18 to 127.68 μg/cm2/h. Passive diffusion of drug showed 46.22 ± 5.2 μg/cm2 of ASP retained in 24 h, while US application resulted in 99.07 to 1495.6 μg/cm2 of drug retained in skin in 24 h. Based on the findings from optimization studies, 30 min of US application, with amplitude of 27–28, and simultaneous application mode was found to achieve the optimal transdermal drug flux, with slightly lower retention values in skin.
The study found that the sonophoretic transdermal permeation and retention of ASP in vitro could be optimized using response surface methodology.
KeywordsAsenapine maleate Transdermal Ultrasound Sonophoresis Design of Experiments Response surface methodology
The authors are thankful to Orbicular Pharmaceutical Technologies Pvt. Ltd., Hyderabad, India for the gift sample of asenapine maleate, and to Manipal Academy of Higher Education, Manipal, India, for providing the facilities required to conduct the research work.
Compliance with Ethical Standards
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors.
- 2.https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022117s000_ChemR.pdfWO2010127674A1. Accessed on 27-09-2018.
- 3.Van Der Sterren JEM, Van Den Heuvel DJM. Intranasal administration of asenapine and pharmaceutical compositions therefore. United State Patent US 2008/0306133 A1. 2008Google Scholar
- 4.Solomon WD. Transdermal compositions of asenapine for the treatment of psychiatric disorders. WO2010127674A1. 2009.Google Scholar
- 20.Huang B, Dong WJ, Yang GY, Wang W, Ji CH, Zhou FN. Dendrimer-coupled sonophoresis-mediated transdermal drug-delivery system for diclofenac. Drug Des Devel Ther. 2015;23(9):3867–76.Google Scholar
- 21.Managuli RS, Kumar L, Chonkar AD, Shirodkar RK, Lewis S, Koteshwara KB, et al. Development and validation of a stability-indicating RP-HPLC method by a statistical optimization process for the quantification of asenapine maleate in lipidic nanoformulations. J Chromatogr Sci. 2016;54:1290–300.CrossRefGoogle Scholar
- 33.https://www.ema.europa.eu/documents/assessment-report/sycrest-epar-public-assessment-report_en.pdf. Accessed on 27-09-2018.